<p class="title">Software services firm HCL Technologies has acquired C3i Solutions for USD 60 million, a move aimed at accelerating the Indian IT firm's growth in life sciences and consumer services.</p>.<p class="bodytext">C3i Solutions is a wholly owned, independently operated subsidiary of Merck & Co, (known as MSD outside the US and Canada).</p>.<p class="bodytext">It provides multi-channel customer engagement services for life sciences and consumer packaged goods (CPG) industries.</p>.<p class="bodytext">"With this acquisition, HCL will complement its broad-based IT and business services capability with the additional depth that C3i has in the life sciences and CPG verticals," the country's fourth-largest software firm HCL Technologies said in a statement.</p>.<p class="bodytext">C3i's expertise in the clinical, pharmacovigilance, and pharma sales support domains and the strong partnership will enable HCL's life sciences customers to become more patient-centric and offer services to IT and business stakeholders, it added.</p>.<p class="bodytext">"C3i's capabilities provide HCL with an innovative and complementary services portfolio and a vast customer base to further strengthen HCL's position as a leading technology solutions provider to the life sciences and consumer industries," HCL Technologies President and CEO C Vijayakumar said.</p>.<p class="bodytext">According to a regulatory filing, HCL Technologies, through its step down subsidiary - HCL America Inc - will acquire 100 percent stock of Telerx Marketing that operates as C3i Solutions.</p>.<p class="bodytext">C3i's revenue for the financial year ended December 31, 2017 stood at USD 199 million. It has over 3,700 people located in the US, India, Bulgaria, China, UK, and Japan.</p>
<p class="title">Software services firm HCL Technologies has acquired C3i Solutions for USD 60 million, a move aimed at accelerating the Indian IT firm's growth in life sciences and consumer services.</p>.<p class="bodytext">C3i Solutions is a wholly owned, independently operated subsidiary of Merck & Co, (known as MSD outside the US and Canada).</p>.<p class="bodytext">It provides multi-channel customer engagement services for life sciences and consumer packaged goods (CPG) industries.</p>.<p class="bodytext">"With this acquisition, HCL will complement its broad-based IT and business services capability with the additional depth that C3i has in the life sciences and CPG verticals," the country's fourth-largest software firm HCL Technologies said in a statement.</p>.<p class="bodytext">C3i's expertise in the clinical, pharmacovigilance, and pharma sales support domains and the strong partnership will enable HCL's life sciences customers to become more patient-centric and offer services to IT and business stakeholders, it added.</p>.<p class="bodytext">"C3i's capabilities provide HCL with an innovative and complementary services portfolio and a vast customer base to further strengthen HCL's position as a leading technology solutions provider to the life sciences and consumer industries," HCL Technologies President and CEO C Vijayakumar said.</p>.<p class="bodytext">According to a regulatory filing, HCL Technologies, through its step down subsidiary - HCL America Inc - will acquire 100 percent stock of Telerx Marketing that operates as C3i Solutions.</p>.<p class="bodytext">C3i's revenue for the financial year ended December 31, 2017 stood at USD 199 million. It has over 3,700 people located in the US, India, Bulgaria, China, UK, and Japan.</p>